Dupilumab
Brand names: Dupixent Pen, Dupixent Syringe
At a glance
- Medicare prescriptions, 2024
- 514,912
- Medicare drug cost
- $2.04B
- Average cost per prescription
- $3,959
- Clinicians who prescribed it
- 15,638
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Limitations of Use: Not for the relief of acute bronchospasm.
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Dermatology 37.1%
- Physician Assistants 17.5%
- Pulmonology 12.4%
- Allergy & Immunology 12.1%
- Nurse Practitioners 10.6%
- ENT (Otolaryngology) 2.6%
- Internal Medicine 1.7%
- Critical Care Medicine 1.4%
- Family Medicine 0.9%
- Mohs Surgery 0.9%
- Dermatopathology 0.7%
- Gastroenterology 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 665% from 2019 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $43.4M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Genzyme Corporation $24.9M
- Regeneron Healthcare Solutions, Inc. $17.0M
- Regeneron Pharmaceuticals, Inc. $962,518
- Sanofi-aventis U.S. LLC $414,241
- Sanofi US Services Inc. $102,538
- Sanofi Pasteur Inc. $353
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma Active, not recruiting · Genzyme Corporation
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care Active, not recruiting · Regeneron Pharmaceuticals, Inc.
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma Active, not recruiting · Regeneron Pharmaceuticals, Inc.
- A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) Active, not recruiting · Genzyme Corporation
- A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have Active, not recruiting · Regeneron Pharmaceuticals, Inc.
- A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Terminated · Sanofi US Services Inc.
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Completed · Regeneron Pharmaceuticals, Inc.
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) Enrolling by invitation · Sanofi US Services Inc.
- Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis Terminated · Sanofi US Services Inc.
- Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Completed · Regeneron Pharmaceuticals, Inc.
- Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Active, not recruiting · Regeneron Pharmaceuticals, Inc.
- Registry of Asthma Patients Initiating DUPIXENT® Completed · Regeneron Pharmaceuticals, Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.